BMI View: Growth in the Spanish pharmaceutical market will remain slow but steady, despite being an
economic outperformer in Western Europe. The ageing population of Spain, and the wider Europe region,
will create significant revenue earning opportunities for drugmake ..."
BMI View: The Spanish pharmaceutical market has struggled in the face of the economic crisis, but is now
expected to return to pre-crisis levels in the coming years. Despite being an economic outperformer in
Western Europe, market growth will remain slow but steady th ..."
BMI View: We maintain our subdued outlook for the Spanish pharmaceutical market. Price caps on
originator medicines have negatively impacted the country's generic drug sector, which lags behind other
European markets. However, new measures to improve access to generic ..."
BMI View: Growth in the Spanish pharmaceutical market will remain sluggish over the coming years.
Despite calls made by pharmaceutical companies for the implementation of a system that adequately
rewards innovation and supports investment in future medicines, ongoing ..."
BMI View: Spain's non-transparent and unpredictable government medicine pricing system and the
implementation of numerous emergency measures to contain pharmaceutical spending will highly disrupt
multinational drugmakers' strategy and revenue streams. Despite the Span ..."
BMI View: The Spanish economy has exited the crisis stage and will post relatively strong real GDP
growth rates compared to most other major eurozone economies over the next few years. However, we
believe government spending will have a negligible impact on growth ove ..."
GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape Spain". The report is an essential source of information on and analysis of the healthcare, regulatory and reimbursement landscape in Sp ..."
BMI View: The deterioration of the Spanish economy and the government's implementation of increasingly
aggressive fiscal austerity policies that focus on cost containment in the healthcare sector seriously hinder
the country's attractiveness to drugmakers. Despite cal ..."
BMI View: Despite the Spanish economy returning to growth in 2014 and picking up steam heading into
2015, we believe that the country's pharmaceutical sector will not follow suit until 2018. Regardless of calls
made by companies for the implementation of a system that ..."
BMI View: The weakened Spanish economy and the government's ongoing multi-faceted strategy to contain
expenditure on prescription medicines by targeting patients, companies and the overall healthcare sector
present challenges to drugmakers operating in the country. Despite call ..."